PTC Therapeutics Inc.(PTCT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PTCT PTC Therapeutics Inc.

六月节休市 06-18 16:00:00 EDT

78.98

+0.45

+0.57%

盘后78.98

+0.000.00%

17:48 EDT

最高80.00	最低78.10	成交量287.03万
今开79.58	昨收78.53	日振幅2.42%
总市值65.38亿	流通市值57.64亿	总股本8,277万
成交额2.27亿	换手率3.93%	流通股本7,298万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PTCT","market":"US","secType":"STK","nameCN":"PTC Therapeutics Inc.","latestPrice":78.98,"timestamp":1781812800000,"preClose":78.53,"halted":0,"volume":2870286,"hourTrading":{"tag":"盘后","latestPrice":78.98,"preClose":78.98,"latestTime":"17:48 EDT","volume":492632,"amount":38907744.96604,"timestamp":1781819282763,"change":0,"changeRate":0,"amplitude":0.00709},"delay":0,"changeRate":0.005730294155099998,"floatShares":72979400,"shares":82774730,"eps":-2.315689,"marketStatus":"六月节休市","change":0.45,"latestTime":"06-18 16:00:00 EDT","open":79.58,"high":80,"low":78.1,"amount":226610744.46588,"amplitude":0.024195,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.315689,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1371700800000,"exchange":"NASDAQ","adjPreClose":78.53,"preHourTrading":{"tag":"盘前","latestPrice":79.4,"preClose":78.53,"latestTime":"09:29 EDT","volume":5416,"amount":426259.45583999995,"timestamp":1781789399999,"change":0.87,"changeRate":0.011079,"amplitude":0.037565},"postHourTrading":{"tag":"盘后","latestPrice":78.98,"preClose":78.98,"latestTime":"17:48 EDT","volume":492632,"amount":38907744.96604,"timestamp":1781819282763,"change":0,"changeRate":0,"amplitude":0.00709},"volumeRatio":0.889265,"impliedVol":0.4668,"impliedVolPercentile":0.3546},"requestUrl":"/m/hq/s/PTCT","defaultTab":"news","newsList":[{"id":"1165503445","title":"花旗集团将PTC Therapeutics评级上调至买入，目标价大幅提升至108美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1165503445","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165503445?lang=zh_cn&edition=full","pubTime":"2026-06-09 18:15","pubTimestamp":1781000119,"startTime":"0","endTime":"0","summary":"花旗集团近日启动了对生物制药公司PTC Therapeutics Inc.的研究覆盖，并将其股票评级从原先的“中性”大幅上调至“买入”。与此同时，该机构将PTC Therapeutics的目标股价从75美元显著提升至108美元，显示出对公司未来发展的强烈信心。这一评级调整和目标价上调，反映了花旗分析师对PTC Therapeutics核心业务、研发管线及市场前景的积极重估。PTC Therapeutics专注于开发针对罕见疾病的RNA靶向疗法，此次获得大型投行的看好，可能预示着其战略执行或产品价值获得了市场更广泛的认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTCT","LU0889565916.HKD","LU0320765992.SGD","BK4139","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194341134","title":"财报前瞻｜PTC Therapeutics Inc.本季度营收预计增34.16%，机构观点偏审慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1194341134","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194341134?lang=zh_cn&edition=full","pubTime":"2026-04-30 11:25","pubTimestamp":1777519517,"startTime":"0","endTime":"0","summary":"PTC Therapeutics Inc.将于2026年05月07日发布财报，市场关注营收回升与盈利修复节奏以及新旧产品线过渡的经营韧性。市场一致预期显示，本季度PTC Therapeutics Inc.营收预计为2.26亿美元，同比增长34.16%；预计调整后每股收益为-0.44美元，同比下降106.37%；预计息税前利润为-1,105.86万美元，同比下降110.06%。上季度PTC Therapeutics Inc.营收为2.13亿美元，同比基本持平；毛利率为14.94%；归属于母公司的净利润为-1.35亿美元，净利率为-81.96%；调整后每股收益为-1.67美元，同比增长22.33%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜PTC Therapeutics Inc.本季度营收预计增34.16%，机构观点偏审慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122274807","title":"PTC Therapeutics公布Votoplam扩展研究Pivot-Hd第24个月中期分析积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1122274807","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122274807?lang=zh_cn&edition=full","pubTime":"2026-04-29 04:06","pubTimestamp":1777406799,"startTime":"0","endTime":"0","summary":"生物制药公司PTC Therapeutics Inc.近日披露了其针对Votoplam药物开展的Pivot-Hd扩展研究在第24个月的中期分析中获得积极顶线数据。该研究旨在评估药物长期疗效与安全性，最新结果显示治疗组在关键指标上维持显著改善趋势。\n此次中期分析覆盖了持续接受治疗的患者群体，数据进一步支持Votoplam在延缓疾病进展方面的潜在价值。公司计划基于这些结果与监管机构沟通后续开发策略，同时继续推进更长期的随访研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4139","LU0889565916.HKD","PTCT","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128872732","title":"财报前瞻｜PTC Therapeutics Inc.本季度营收预计增长19.03%，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1128872732","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128872732?lang=zh_cn&edition=full","pubTime":"2026-02-12 10:54","pubTimestamp":1770864876,"startTime":"0","endTime":"0","summary":"PTC Therapeutics Inc.将于2026年02月19日发布最新季度财报，市场聚焦核心产品放量与费用控制节奏对利润的影响。市场一致预期显示，本季度PTC Therapeutics Inc.总营收预计为2.77亿美元，同比增速19.03%；预计调整后每股收益为0.04美元，同比增幅105.72%；预计息税前利润为3,585.45万美元，同比增幅72.76%。上季度PTC Therapeutics Inc.营收约2.11亿美元，同比增长7.23%；毛利率45.05%；归属母公司净利润1,589.60万美元，净利率7.53%，调整后每股收益0.20美元，同比增长114.39%。综合近期机构对PTC Therapeutics Inc.的观点，偏谨慎的声音占比更高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜PTC Therapeutics Inc.本季度营收预计增长19.03%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124538092","title":"PTC Therapeutics Inc. 交易条款包含三项潜在额外付款 每项价值2000万美元——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1124538092","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124538092?lang=zh_cn&edition=full","pubTime":"2025-12-30 05:23","pubTimestamp":1767043402,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件显示，PTC Therapeutics Inc. 的资产出售交易条款中包含了三项潜在的额外付款安排，每项付款金额高达2000万美元。\n这一财务安排突显了该交易可能为PTC Therapeutics带来可观的后续收益。文件表明，这些额外付款的触发将基于特定的里程碑或业绩条件的达成。\n此类结构化付款条款在生物技术行业的资产交易中较为常见，通常用于在交易完成后，根据被出售资产或技术的后续开发进展或商业化成功程度，向出售方提供额外的价值回报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0320765992.SGD","BK4139","PTCT","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158618398","title":"PTC Therapeutics与Royalty Pharma签署购买协议第二号修正案","url":"https://stock-news.laohu8.com/highlight/detail?id=1158618398","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158618398?lang=zh_cn&edition=full","pubTime":"2025-12-30 05:15","pubTimestamp":1767042913,"startTime":"0","endTime":"0","summary":"PTC Therapeutics公司、Royalty Pharma Investments 2019 Icav基金以及Royalty Pharma Plc共同宣布，三方已正式签署购买协议的第二号修正案。此次修订旨在优化原有条款，进一步明确各方的权利与义务。\n该修正案涉及对原始购买协议中特定条款的调整，反映出合作方在不断变化的市场环境中寻求更高效协作的努力。协议的更新将有助于提升合作透明度，为未来业务发展奠定更稳固的基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0320765992.SGD","PTCT","LU0889565916.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195993385","title":"PTC Therapeutics宣布Sephience™（Sepiapterin）获得日本对苯丙酮尿症（PKU）患者的治疗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1195993385","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195993385?lang=zh_cn&edition=full","pubTime":"2025-12-22 20:02","pubTimestamp":1766404936,"startTime":"0","endTime":"0","summary":"PTC Therapeutics宣布Sephience™（Sepiapterin）获得日本对苯丙酮尿症（PKU）患者的治疗批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","BK4139","LU0109394709.USD","PTCT","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517334467","title":"PTC Therapeutics(PTCT.US)获Scotiabank首次覆盖，给予与大盘持平评级, 目标价55.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517334467","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517334467?lang=zh_cn&edition=full","pubTime":"2025-03-08 06:42","pubTimestamp":1741387360,"startTime":"0","endTime":"0","summary":"PTC Therapeutics(PTCT.US)获Scotiabank首次覆盖，给予与大盘持平评级, 目标价55.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08064248605342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PTC","PTCT","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517529624","title":"Ptc Therapeutics, Inc.2024财年实现净利润-3.63亿美元，同比增加42.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517529624","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517529624?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363251,"startTime":"0","endTime":"0","summary":"3月8日，Ptc Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-3.63亿美元，同比增加42.11%；其中营业收入为8.07亿美元，同比减少13.97%，每股基本收益为-4.73美元。从资产负债表来看，Ptc Therapeutics, Inc.总负债28.15亿美元，其中短期债务13.36百万美元，资产负债比为0.61，流动比率为2.36。机构评级：截至2025年3月8日，当前有15家机构对Ptc Therapeutics, Inc.目标价做出预测，其中目标均价为62.67美元，其中最低目标价为41.00美元，最高目标价为113.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000221a2647f70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000221a2647f70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","PTCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516677198","title":"Ptc Therapeutics, Inc.盘中异动 股价大跌5.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677198","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516677198?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:36","pubTimestamp":1741098993,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时36分，Ptc Therapeutics, Inc.股票出现波动，股价大幅跳水5.52%。Ptc Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.17%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Protagenic Therapeutics, Inc.、Exicure, Inc.涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1082.56%、1072.80%、425.75%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Hepion Pharmaceuticals, Inc.、Adma Biologics Inc，振幅分别为23.30%、22.25%、12.57%。Ptc Therapeutics, Inc.公司简介：PTC Therapeutics Inc 是一家生物制药公司，专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223634abe7f167&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223634abe7f167&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","LENZ","PTCT","LU0320765992.SGD","LU0109394709.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516727371","title":"小摩：维持PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价由74.00美元调整至72.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516727371","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516727371?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:45","pubTimestamp":1740761122,"startTime":"0","endTime":"0","summary":"小摩：维持PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价由74.00美元调整至72.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/01004548469593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","PTC","PTCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142137500","title":"PTC Therapeutics 2024年第四季度调整后每股收益$(0.85) 低于预期$(0.66)，销售额$2.13亿 低于预期$2.3244亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1142137500","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142137500?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:18","pubTimestamp":1740691133,"startTime":"0","endTime":"0","summary":"PTC Therapeutics报告季度每股亏损$，低于分析师一致预期的$，差距为28.79%。公司报告季度销售额为$2.13亿美元，低于分析师一致预期的$2.3244亿美元，差距为8.36%。与去年同期的$3.0706亿美元销售额相比，同比下降30.63%。以上内容来自Benzinga Earnings专栏，原文如下：PTC $Therapeutics$  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 28.79 percent. This is a 254.17 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $213.00 million which missed the analyst consensus estimate of $232.44 millio","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTCT","PTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512198714","title":"加拿大皇家银行：维持PTC Therapeutics(PTCT.US)评级，由优于大市调整至优于大市评级, 目标价由60.00美元调整至63.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512198714","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512198714?lang=zh_cn&edition=full","pubTime":"2025-02-19 01:58","pubTimestamp":1739901520,"startTime":"0","endTime":"0","summary":"加拿大皇家银行：维持PTC Therapeutics(PTCT.US)评级，由优于大市调整至优于大市评级, 目标价由60.00美元调整至63.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19015848243282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PTCT","LENZ","PTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508999123","title":"坎托菲茨杰拉德公司：维持PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价由76.00美元调整至113.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2508999123","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508999123?lang=zh_cn&edition=full","pubTime":"2025-02-04 00:54","pubTimestamp":1738601652,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：维持PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价由76.00美元调整至113.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/04005447942318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PTCT","PTC","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508371144","title":"Ptc Therapeutics, Inc.盘中异动 快速上涨5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508371144","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508371144?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:51","pubTimestamp":1738594261,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时51分，Ptc Therapeutics, Inc.股票出现波动，股价快速拉升5.11%。Ptc Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.42%。其相关个股中，Hcw Biologics Inc.、Gh Research Plc、Invivyd, Inc.涨幅较大，Hcw Biologics Inc.、Briacell Therapeutics Corp.、Cyclerion Therapeutics, Inc.较为活跃，换手率分别为428.16%、363.02%、229.18%，振幅较大的相关个股有Hcw Biologics Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Briacell Therapeutics Corp.，振幅分别为97.05%、50.76%、36.85%。Ptc Therapeutics, Inc.公司简介：PTC Therapeutics Inc 是一家生物制药公司，专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203225101abc10be7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203225101abc10be7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","BK4139","LU0889565916.HKD","PTCT","LENZ","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503464870","title":"坎托菲茨杰拉德公司：维持PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价由80.00美元调整至76.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503464870","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503464870?lang=zh_cn&edition=full","pubTime":"2025-01-15 20:53","pubTimestamp":1736945635,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：维持PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价由80.00美元调整至76.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/15205347495124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PTCT","PTC","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2490019466","title":"Ptc Therapeutics, Inc.盘中异动 快速拉升6.08%报50.98美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490019466","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490019466?lang=zh_cn&edition=full","pubTime":"2024-12-10 22:31","pubTimestamp":1733841077,"startTime":"0","endTime":"0","summary":"北京时间2024年12月10日22时31分，Ptc Therapeutics, Inc.股票出现波动，股价快速拉升6.08%。Ptc Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.25%。其相关个股中，Chimerix, Inc.、Uniqure N.V.、Klotho Neurosciences Inc C/Wts 21/06/2029 涨幅较大，Psyence Biomedical Ltd.、Processa Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals, Inc.较为活跃，换手率分别为1643.12%、399.04%、84.92%，振幅较大的相关个股有Newamsterdam Pharma Company N.V.、Lava Therapeutics N.V.、Silexion Therapeutics Corp，振幅分别为10.21%、9.95%、9.70%。Ptc Therapeutics, Inc.公司简介：PTC Therapeutics Inc 是一家生物制药公司，专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223117ab6cf51e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223117ab6cf51e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PTCT","LU0889565916.HKD","LENZ","LU0320765992.SGD","BK4139","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2488492247","title":"Ptc Therapeutics, Inc.盘中异动 下午盘股价大跌5.17%报49.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488492247","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488492247?lang=zh_cn&edition=full","pubTime":"2024-12-04 03:06","pubTimestamp":1733252760,"startTime":"0","endTime":"0","summary":"北京时间2024年12月04日03时06分，Ptc Therapeutics, Inc.股票出现异动，股价急速跳水5.17%。Ptc Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.80%。Ptc Therapeutics, Inc.公司简介：PTC Therapeutics Inc 是一家生物制药公司，专注于口服小分子疗法的发现、开发和商业化。消息层面，截至03时06分，《PTC Therapeutics与诺华制药签署亨廷顿病药物许可协议》资讯为影响Ptc Therapeutics, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204030600abf37014&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204030600abf37014&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","LENZ","PTCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2488708526","title":"Ptc Therapeutics, Inc.股价飙升15.43% 市值涨6.03亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488708526","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488708526?lang=zh_cn&edition=full","pubTime":"2024-12-02 22:31","pubTimestamp":1733149882,"startTime":"0","endTime":"0","summary":"北京时间2024年12月02日22时31分，Ptc Therapeutics, Inc.股票出现波动，股价大幅上涨15.43%。Ptc Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。其相关个股中，Senti Biosciences, Inc.、Purple Biotech Ltd、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Purple Biotech Ltd、Senti Biosciences, Inc.、Revelation Biosciences, Inc.较为活跃，换手率分别为643.05%、635.36%、201.02%，振幅较大的相关个股有Senti Biosciences, Inc.、Renovaro Inc.、Precigen, Inc.，振幅分别为16.20%、6.61%、6.40%。Ptc Therapeutics, Inc.公司简介：PTC Therapeutics Inc 是一家生物制药公司，专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202223122a2669857&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202223122a2669857&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","LU0889565916.HKD","BK4139","LU0109394709.USD","LU0320765992.SGD","PTCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2488067958","title":"PTC Therapeutics(PTCT.US)与诺华制药(NVS.US)签署亨廷顿病药物许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2488067958","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488067958?lang=zh_cn&edition=full","pubTime":"2024-12-02 21:23","pubTimestamp":1733145808,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美国生物制药公司PTC Therapeutics的股价周一盘前上涨21%，此前该公司与诺华制药签署了PTC518亨廷顿病项目的独家全球许可和合作协议。PTC518目前正在进行2期PIVOT-HD试验，并显示出良好的安全性和耐受性。该协议预计将于2025年第一季度完成。根据协议，PTC Therapeutics 将获得10亿美元的预付款，高达19亿美元的开发、监管和销售里程碑，在美国的利润分成为40%，并在美国以外的地区获得两位数的销售分层版税。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BJJMRZ35.SGD","LU0320765992.SGD","BK4139","LU2362541273.HKD","LU0109394709.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","PTC","LU1951198990.SGD","IE00BFTCPJ56.SGD","LU1721428347.USD","IE0002141913.USD","BK4554","LU2362540622.SGD","LENZ","LU1951200564.SGD","BK1191","LU2506952337.HKD","BK4007","IE0009355771.USD","LU0889565916.HKD","BK4023","BK1574","PTCT","BK4578","BK4576","BK4585","IE00BJT1NW94.SGD","LU2477742899.HKD","NVS","LU0211331839.USD","BK4532","BK4588","01477","LU2362541513.USD","LU1923623000.USD","LU2506952410.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ptcbio.com","stockEarnings":[{"period":"1week","weight":0.0572},{"period":"1month","weight":0.1233},{"period":"3month","weight":0.2095},{"period":"6month","weight":0.0052},{"period":"1year","weight":0.5661},{"period":"ytd","weight":0.0398}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ptc Therapeutics, Inc.于1998年3月31日注册成立为一家特拉华州公司。 PTC Therapeutics股份有限公司是一家生物制药公司，专注于用于转录后控制过程中的口服药，专有的小分子药物的发现和开发。同时该公司的研发计划针对于多个治疗领域，公司特别专注于孤儿和超孤儿混乱疾病的治疗的开发和商业化。公司主导的候选产品是ataluren，该产品用于治疗过程中所出现的一种被称为无义突变基因突变的遗传性疾病的治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.615385,"avgChangeRate":0.092699},{"month":2,"riseRate":0.538462,"avgChangeRate":0.002415},{"month":3,"riseRate":0.384615,"avgChangeRate":-0.067406},{"month":4,"riseRate":0.461538,"avgChangeRate":0.01954},{"month":5,"riseRate":0.538462,"avgChangeRate":0.031395},{"month":6,"riseRate":0.615385,"avgChangeRate":0.053729},{"month":7,"riseRate":0.666667,"avgChangeRate":0.026829},{"month":8,"riseRate":0.692308,"avgChangeRate":0.062649},{"month":9,"riseRate":0.538462,"avgChangeRate":0.038954},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.075074},{"month":11,"riseRate":0.692308,"avgChangeRate":0.134491},{"month":12,"riseRate":0.615385,"avgChangeRate":0.031464}],"exchange":"NASDAQ","name":"PTC Therapeutics Inc.","nameEN":"PTC Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PTC Therapeutics Inc.(PTCT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PTC Therapeutics Inc.(PTCT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PTC Therapeutics Inc.,PTCT,PTC Therapeutics Inc.股票,PTC Therapeutics Inc.股票老虎,PTC Therapeutics Inc.股票老虎国际,PTC Therapeutics Inc.行情,PTC Therapeutics Inc.股票行情,PTC Therapeutics Inc.股价,PTC Therapeutics Inc.股市,PTC Therapeutics Inc.股票价格,PTC Therapeutics Inc.股票交易,PTC Therapeutics Inc.股票购买,PTC Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PTC Therapeutics Inc.(PTCT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PTC Therapeutics Inc.(PTCT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}